HeartBeam, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BEAT research report →
Range $2 – $2
Price Chart
About the company
HeartBeam, Inc. is a development stage company, which engages in cardiovascular diagnostic technology. Its electrocardiogram (ECG) collection device provides physicians with cardiac diagnostic information for a patient that is outside of a medical institution.
- CEO
- Branislav Vajdic
- IPO
- 2021
- Employees
- 16
- HQ
- Santa Clara, CA, US
Get TickerSpark's AI analysis on BEAT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $17.42M
- P/E
- -0.67
- Fwd P/E
- 1.10
- PEG
- -0.01
- P/S
- 0.00
- P/B
- 2.47
- EV/EBITDA
- -0.65
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -402.72%
- ROIC
- -285.16%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-21,139,000
- Net Income
- $-21,015,000-8.1%
- EPS
- $-0.62+15.1%
- OCF Growth
- +3.3%
- FCF Growth
- +0.6%
- 52W High
- $4.00
- 52W Low
- $0.27
- 50D MA
- $0.42
- 200D MA
- $0.77
- Beta
- -0.85
- RSI (14)
- 31
- Avg Volume
- 7.50M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
HeartBeam said Q3 was a milestone quarter for its heart attack detection program, with FDA alignment on a 510(k) path, encouraging clinical data, and sharply lower cash burn.· November 12, 2026
- FDA alignment on a 510(k) pathway is a key de-risking step, and management expects pivotal study design to be finalized in Q4 2026.
- ALIGN-ACS data were presented at TCT 2026, with HeartBeam’s 3D ECG described as as accurate as standard 12-lead ECG and showing higher specificity.
- Cash burn improved materially: net cash used in operations fell to $2.6 million in Q3, and full-year operating cash outflow guidance was reduced to $12 million-$12.5 million.
- Management said the U.S. pivotal trial could start in Q1 2027, with a roughly 300-patient study size likely, though final details are still being negotiated with FDA.
- The company is building reimbursement, AI, and partnership options, but commercialization is still early and not yet a major revenue driver.
HeartBeam reported net cash used in operating activities of $2.6 million in Q3 2026, down 23% from Q2 2026 and down 18% from the prior-year quarter. Total operating expenses were $3.5 million, down 32% sequentially and down 35% year over year; SG&A was $1.3 million versus $2.0 million last year, and R&D was $2.1 million versus $3.3 million last year. Net loss was $3.0 million, compared with $5.3 million in Q3 2025 and $5.0 million in Q2 2026. Cash and cash equivalents were $6.1 million at September 30, 2026, and after roughly $4 million of net ATM proceeds post-quarter, pro forma cash was about $10.1 million. For full-year 2026, management expects net operating cash outflow of $12 million to $12.5 million, versus prior guidance of staying below $14 million; baseline Q4 operating cash outflow is expected to be below $2.5 million. On the clinical side, management said ALIGN-ACS enrolled 132 adults, HeartBeam specificity was 81.8% versus 71.4% for standard 12-lead ECG, sensitivity was 60.2% versus 63.0%, and STEMI sensitivity was 82.9% versus 83.8% for 12-lead ECG. The company also said the 3D 3-lead and standard 12-lead ECG had the same AUC, and all patients in the study were able to obtain a HeartBeam recording. Forward-looking, management expects the U.S. pivotal study to begin in Q1 2027, possibly earlier, and estimates the study may be around 300 patients across roughly 8 to 10 centers.
Richard Ferrari framed the quarter as a major execution step, saying Q3 was a “fabulous quarter” and emphasizing that the company now has a clearer regulatory path, better FDA engagement, and a tighter focus on heart attack detection. He highlighted Breakthrough Device Designation, TAP participation, the 510(k) path, and the size of the market opportunity, repeatedly describing the next phase as “pure execution.” His tone was confident and upbeat, while also insisting that the company is prioritizing milestones that can drive long-term shareholder value.
Tim Cruickshank focused on capital efficiency and the drop in cash burn. He said net cash used in operating activities was $2.6 million in Q3, operating expenses were $3.5 million, and the net loss was $3.0 million, all significantly lower than prior periods. He attributed the decline to reduced development and consulting spend, lower costs from completing the ALIGN-ACS pilot study, and lower employee costs, and said cash was $6.1 million at quarter-end, rising to about $10.1 million pro forma after the ATM raise. He reiterated that Q4 operating cash outflow should stay below $2.5 million and that full-year 2026 operating cash outflow should land between $12 million and $12.5 million.
Analysts focused on the pivotal study design, asking about trial size, endpoints, enrollment timing, and what evidence FDA would require for 510(k) clearance. Management said the most likely study size is around 300 patients, likely across 8 to 10 centers, with final endpoints still being negotiated, but they believe ALIGN-ACS is broadly mirroring the proposed design. Questions also covered commercialization and monetization of the already cleared arrhythmia product; management said that is not the current focus, though concierge practices are already using the device and the company is open to strategic discussions. A webcast question about Nasdaq compliance drew reassurance that HeartBeam is in communication with Nasdaq, expects an extension, and believes it can regain compliance organically.
The company has a clearer regulatory road map than it had previously, with management saying FDA alignment on 510(k) and Breakthrough/TAP participation should shorten the path to pivotal testing and eventual clearance. Clinical data were presented as encouraging, with HeartBeam’s 3D ECG showing comparable performance to 12-lead ECG in ALIGN-ACS and strong signals on usability and reader agreement. At the same time, the company sharply reduced spending and extended its cash runway, which gives it more room to reach the next milestones.
The business is still pre-commercial for its main heart attack detection product, and management repeatedly said final study size, endpoints, and timing are not yet locked in because FDA discussions are ongoing. The clinical program remains subject to execution risk, with the pivotal study only expected to start in Q1 2027 and clearance timing still uncertain. Revenue remains modest, reimbursement is unresolved, and management acknowledged that monetization of the existing arrhythmia clearance is not a major focus right now.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 82.1%
- Shares Outstanding
- 63.31M
- Float Shares
- 51.99M
of shares held by institutions
42 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Capital Management LLC | 2.14M | 0 |
| Vanguard Group Inc | 1.08M | ▼ 34.18K |
| Blackrock, Inc. | 980.67K | ▼ 7.17K |
| Corsair Capital Management, L.P. | 662.50K | ▼ 250.00K |
| Bleichroeder LP | 625.00K | 0 |
| Geode Capital Management, LLC | 480.46K | ▲ 1.08K |
| Sigma Planning Corp | 387.20K | ▲ 139.50K |
| Smith Salley Wealth Management | 367.65K | 0 |
| O'Shaughnessy Asset Management, LLC | 280.16K | ▲ 71.97K |
| Ritholtz Wealth Management | 280.16K | ▲ 71.97K |
| Vanguard Fiduciary Trust Co | 274.82K | 0 |
| Beacon Pointe Advisors, LLC | 247.06K | 0 |
Held by 26 ETFs
Biggest fund positions in BEAT by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 2, 26 | Elfrink Willem | other | 93,750 |
| Oct 2, 26 | Elfrink Willem | other | 93,750 |
| Oct 2, 26 | Ferrari Richard | other | 125,000 |
| Oct 2, 26 | Ferrari Richard | other | 125,000 |
| Oct 2, 26 | Ferrari Richard | other | 90,625 |
| Oct 2, 26 | JAFF MICHAEL R | other | 93,750 |
| Oct 2, 26 | JAFF MICHAEL R | other | 37,500 |
| Oct 2, 26 | Ortigas-Wedekind Marga | other | 93,750 |
| Oct 2, 26 | Ortigas-Wedekind Marga | other | 81,250 |
| Oct 2, 26 | Nelson Kenneth Warwick III | other | 93,750 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BEAT coverage
Recent articles, reports, and earnings notes.
No research on BEAT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BEAT report →Bet on 5 Top-Ranked Stocks With Rising P/E
zacks.com · Nov 20
HeartBeam, Inc. (BEAT) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 12
HeartBeam Reports Third Quarter 2026 Results
businesswire.com · Nov 12
HeartBeam to Host Third Quarter 2026 Results Conference Call on Thursday, November 12, 2026 at 4:30 p.m. Eastern Time
businesswire.com · Nov 3
HeartBeam Announces Positive Heart Attack Pilot Study Results at TCT 2026: Patient-Recorded 3D ECG Shown to Be as Accurate as Standard 12-Lead ECG
businesswire.com · Nov 2
HeartBeam to Present Results of ALIGN-ACS Study for Heart Attack Assessment at TCT 2026 on November 1, 2026
businesswire.com · Oct 28
HEADSTART-ACS Completes Enrollment Ahead of Schedule, the Largest Heart Attack Detection Study to Date Using HeartBeam Technology
businesswire.com · Oct 21
HeartBeam Joins European EXIT-CVD Research Consortium to Advance At-Home ECG Monitoring for Early Detection of Acute Coronary Syndrome (ACS) in High-Risk Patients
businesswire.com · Oct 15
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.